This video examines clinical and genomics data from the NCI 9012 trial, which studied abiraterone combined with a PARP inhibitor in patients with metastatic castration-resistant prostate cancer.
Maha H. Hussain, MD
We will review how PARP inhibitors function as a class, review the molecular features that sensitize cancer cells to this therapy, and discuss the data supporting its potential for patients with prostate cancer.
This review will discuss recently FDA-approved agents for advanced prostate cancer and those under investigation in phase III trials.
Bladder cancer is the fifth most common cancer diagnosed in the
United States. Prognosis for this disease is dependent on both tumor
stage and grade. Radical cystectomy has been the standard treatment
for muscle-invasive local disease; however, combined-modality approaches
with the use of chemotherapy are gaining momentum with
data suggesting survival improvement. Patients with metastatic disease
have poor long-term survival rates despite systemic multiagent chemotherapy.
A variety of agents, including newer cytotoxic drugs and biologically
targeted agents, are under investigation to determine the most
effective regimen. The special needs of specific patient populations,
such as the elderly, those with a suboptimal performance status, and
patients with medical comorbidities have gained more attention.
Progress in the treatment of this disease is dependent on supporting
ongoing and future clinical trials.